Identification of miRNAs that target Fcγ receptor-mediated phagocytosis during macrophage activation syndrome

Kontham Kulangara Varsha1, Xiaoming Yang1, Alkeiver S Cannon1

  • 1Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina School of Medicine, Columbia, SC, United States.

PubMed

Insights

MicroRNAs (miRNAs) drive macrophage hyperactivation in Macrophage Activation Syndrome (MAS) by increasing Fc gamma receptor-mediated phagocytosis and IL-12 production. This suggests miRNA-based therapies for MAS treatment.

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • Macrophage Activation Syndrome (MAS) is a severe complication of systemic juvenile arthritis and shares features with COVID-19 hyperinflammation.
  • The precise mechanisms activating macrophages in MAS are not fully understood.
  • Identifying these mechanisms is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) in macrophage activation during MAS.
  • To elucidate the molecular pathways, including phagocytosis and cytokine production, regulated by miRNAs in MAS.
  • To explore potential therapeutic targets and diagnostic markers for MAS.

Main Methods:

  • Utilized a murine model of MAS to study macrophage activity.
  • Performed gene expression profiling to identify upregulated pathways and genes.
  • Analyzed miRNA targets using transcriptome data from both murine models and human MAS patients.

Main Results:

  • MAS induced increased macrophage populations and phagocytosis in the liver.
  • Upregulation of Fc gamma receptor-mediated phagocytosis (FGRP) and Interleukin-12 (IL-12) production was observed.
  • Specific miRNAs (miR-136-5p, miR-501-3p) were found to increase Fcgr gene expression and phagocytosis, while others (miR-129-1-3p, miR-150-3p) induced IL-12.

Conclusions:

  • Demonstrated a novel role for specific miRNAs in MAS pathogenesis.
  • Highlighted the involvement of FGRP and IL-12 pathways in MAS.
  • Proposed miRNA mimic therapy and FCGR gene overexpression as potential therapeutic and diagnostic strategies for MAS.